Evidence map›Paper›PMID 38252228›Full record

ArticleAnnals of nuclear medicine2024

Visual and whole-body quantitative analyses of

Masatoshi Hotta, Ida Sonni, Pan Thin, Kathleen Nguyen, Linda Gardner, Liliana Ciuca, Artineh Hayrapetian, Meredith Lewis, David Lubin, Martin Allen-Auerbach

Abstract read

PubMed Publisher

In one paragraph

Article in Annals of nuclear medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it

0cells of the map it votes in

5citing papers in PubMed, 1 pooled it

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

ESR Essentials: role of PET/CT in neuroendocrine tumors-practice recommendations by the European Society for Hybrid, Molecular and Translational Imaging.European radiology · 2025
Guideline
Semiquantitative SSTR PET metrics show molecular-morphologic discordance after 177Lu-DOTATATE in gastroenteropancreatic neuroendocrine neoplasms: an exploratory paired target-lesion analysis.Annals of nuclear medicine · 2026
Article
PET/CT contouring techniques in neuroendocrine neoplasms: a state-of-the-art scoping review.EJNMMI reports · 2026
Review
Enhancing PRRT Outcome Prediction in Neuroendocrine Tumors: Aggregated Multi-Lesion PET Radiomics Incorporating Inter-Tumor Heterogeneity.Cancers · 2025
Article
Recent advances in theranostics and oncology PET: emerging radionuclides and targets.Annals of nuclear medicine · 2025
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Masatoshi Hotta *Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA. m.hotta.11.11@gmail.com.ORCID http://orcid.org/0000-0001-6790-8804

Ida Sonni *Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.

Pan ThinDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.

Kathleen NguyenDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.

Linda GardnerDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.

Liliana CiucaDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.

Artineh HayrapetianDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.

Meredith LewisDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.

David LubinDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.

Martin Allen-AuerbachDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSomatostatin receptors (SSTR) represent an ideal target for nuclear theranostics applications in neuroendocrine tumors (NET). Studies suggest that high uptake on SSTR-PET is associated with response to SSTR peptide receptor radionuclide therapy (PRRT). The purpose of this study was to evaluate the role of baseline whole-body (WB)

methodsPatients with NET who underwent at least 4

resultsForty patients (F/M: 21/19; 34/40 with gastro-entero-pancreatic (GEP) NET, 6/40 with non-GEP NET) were included in the analysis. The median follow-up period after the 4th PRRT cycle was 25.7 months (range 15.2-59.1). Fourteen/40 (35%) patients showed radiologic response (RECIST PR). PFS event was observed in 17/40 (42.5%) patients. Thirteen/40 (32.5%) patients had SSTR-PET-negative lesions at baseline. Higher WB-SUVmean and H-SUVmax were associated with better response (p = 0.015 and 0.005, respectively). The presence of SSTR-PET-negative lesions and lower WB-SUVmean were associated with shorter PFS (p = 0.026 and 0.008, respectively).

conclusionVisual and quantitative analyses of baseline SSTR-PET can yield valuable information to prognosticate outcomes after

Indexed as

Neuroendocrine TumorsOrganometallic CompoundsPositron-Emission TomographyRadionuclide ImagingHumansOctreotidePositron Emission Tomography Computed TomographyPrognosisReceptors, SomatostatinRetrospective Studiescopper dotatate CU-64OctreotideOrganometallic CompoundsReceptors, Somatostatin177Lu-DOTATATE68 Ga-DOTATATENeuroendocrine tumorPET/CTPRRT

Identifiers

PMID38252228

DOI10.1159/000343612

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.